ORYZON and CANCER RESEARCH UK’S Paterson Institute for Cancer Research have started a collaborative research project on therapeutic uses of LSD1 inhibitors for Acute Leukaemia
The Cancer Research UK-funded research is led by Dr Tim Somervaille, Group Leader of the Cancer Research UK Leukaemia Biology group at the Paterson Institute for Cancer Research and Honorary Consultant in Haematology at The Christie NHS Foundation Trust in Manchester (UK).
The collaboration is focused to achieve a deeper understanding of the inhibition of histone lysine demethylation as a stopper mechanism for onset and progression of acute leukaemia.
LSD1 inhibitors reduced tumour load especially in acute leukaemia models by targeting leukaemia stem cells, while normal myeloid progenitor cells were spared.
Oryzon announces that ORYZON and Cancer Research UK’s Paterson Institute for Cancer Research have entered into a collaboration to further study the potential of highly potent and highly-selective Oryzon LSD1 inhibitors in the treatment of acute leukemia. This collaborative research is performed by Dr Tim Somervaille’s group.
Cancer Research UK scientist Dr Tim Somervaille is a specialist in leukaemia and in LSD1. He was trained in Medicine at St Mary’s Hospital Medical School (Imperial College London) and University College London. He specialised in Clinical Haematology at University College London, where he also obtained a PhD as a Medical Research Council Clinical Training Fellow. Later, as a Leukaemia Research Fund Senior Clinical Fellow, he spent four years in Professor Michael Cleary’s laboratory undertaking postdoctoral studies in leukaemia. Currently he is leader of the Cancer Research UK Leukaemia Biology group at Cancer Research UK’s Paterson Institute for Cancer Research and also Honorary Consultant in Haematology at The Christie NHS Foundation Trust.
